Novo Integrated Sciences, Inc. (NVOS)
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services.
It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services.
It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations.
In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors.
Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions.
The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington.
Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.
|IPO Date||Sep 22, 2017|
|Industry||Medical Care Facilities|
|CEO||Mr. Robert Mattacchione|
11120 Ne 2nd Street, Suite 100
Bellevue, Washington 98004
|Fiscal Year||September - August|
|Robert Mattacchione||Chairman and Chief Executive Officer|
|Christopher Mehlin David||Chief Operating Officer, President and Director|
|James Zsebok||Principal Financial Officer|
|Dr. Indrajit Sinha Ph.D.||Chief Science Officer|
|David Brien BSc.PT, BSc.Bio||Senior Vice President of Clinical Operations - Eastern Ontario|
|Dr. Joseph M. Chalil FACHE, M.B.A., M.D.||Chief Medical Officer and Chairman of Medical Advisory Board|
Latest SEC Filings
|Mar 27, 2023||8-K||Current Report|
|Mar 24, 2023||8-K||Current Report|
|Mar 1, 2023||8-K||Current Report|
|Feb 14, 2023||8-K||Current Report|
|Feb 10, 2023||SC 13G/A||[Amend] Statement of acquisition of beneficial ownership by individuals|
|Jan 30, 2023||8-K||Current Report|
|Jan 26, 2023||8-K||Current Report|
|Jan 17, 2023||NT 10-Q||Notification of inability to timely file Form 10-Q or 10-QSB|
|Jan 17, 2023||8-K||Current Report|
|Jan 6, 2023||8-K||Current Report|